Etanercept combined with methotrexate for high-need psoriasis

British Journal of Dermatology

Volumn 159, Issue 2, 2008, Pages 460-463

  Driessen, R J B ^a   Van De Kerkhof, P C M ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combination; Efficacy; Etanercept; Methotrexate; Psoriasis; Safety

Indexed keywords

ETANERCEPT; METHOTREXATE;

ACTINIC KERATOSIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COMMON COLD; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLICULITIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HERPES LABIALIS; HUMAN; INFLUENZA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION; MALE; NEOPLASM; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RATING SCALE; SIDE EFFECT; SKIN CANCER; SORE THROAT; URINARY TRACT INFECTION;

ADULT; DERMATOLOGIC AGENTS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47549108642     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08669.x     Document Type: Article

References (13)

1. Dubertret L, Sterry W, Bos JD et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006 155 : 170 81.
2. ® (etanercept). Summary of Product Characteristics. Wyeth Europa Ltd., Taplow, UK (2007).
3. Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006 10 : 1 233, i-iv.
4. van Riel PL, Taggart AJ, Sany J et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006 65 : 1478 83.
5. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006 54 : 1063 74.
6. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004 363 : 675 81.
7. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 340 : 253 9.
8. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 44.
9. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002 4 : 266 73.
10. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006 355 : 704 12.
11. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007 65 : 168 73.
12. Methotrexate. Summary of Product Characteristics. Pharmachemie BV., Haarlem, The Netherlands (2006).
13. Berends MA, Snoek J, de Jong EM et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006 24 : 805 11.